Envestnet Portfolio Solutions Inc. Has $1.91 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 36.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,684 shares of the biopharmaceutical company's stock after purchasing an additional 713 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,912,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Amundi increased its holdings in shares of Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock valued at $495,639,000 after buying an additional 22,538 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock valued at $215,562,000 after buying an additional 1,108 shares during the period. Finally, Candriam S.C.A. grew its position in Regeneron Pharmaceuticals by 3.6% during the fourth quarter. Candriam S.C.A. now owns 261,498 shares of the biopharmaceutical company's stock worth $186,273,000 after buying an additional 8,973 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Trading Down 4.1 %

Regeneron Pharmaceuticals stock traded down $26.86 during midday trading on Tuesday, hitting $634.14. 852,233 shares of the stock were exchanged, compared to its average volume of 635,607. The stock has a market capitalization of $69.33 billion, a PE ratio of 16.57, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a fifty day simple moving average of $688.31 and a two-hundred day simple moving average of $809.71. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $11.86 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Finally, Citigroup dropped their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.